Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial (Q46378100)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David J. Brooks

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

Fabrizio Stocchi

object named as

F Stocchi

6

0 references

5

object named as

W Poewe

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

Wolfgang H. Oertel

4

object named as

W Oertel

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

author name string

O Rascol

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

E Melamed

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

E Tolosa

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

LARGO study group

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

365

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

9463

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

947-954

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Core assessment program for intracerebral transplantations (CAPIT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Limitations of current Parkinson's disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2971083-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(05)71083-7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15766996

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46378100&oldid=2108708005"